11.00 - 11.10
Introduction
11.10 - 12.10
SESSION I – MYELOPROLIFERATIONS
[session in Polish]
11.10 - 11.25
Optimizing selection of JAK inhibitors in myelofibrosis
11.25 - 11.40
Therapeutic goals in verrucous melanoma and spontaneous hyperplasia: strategies for achievement
11.40 - 11.55
Treatment of advanced phase CML
12.10 - 12.25
Coffee break
12.25 - 13.25
SESSION II – MDS/PNH
[session in Polish]
12.25 - 12.40
Managing low-risk MDS: current approaches and future perspectives
12.40 - 12.55
High-risk MDS: defining and treating
12.55 - 13.10
Optimising therapy for PNH
13.25 - 14.10
Sponsored lunch session [parallel session]:
[session in Polish]
13.25 - 13.40
Sponsored lecture I
13.40 - 13.55
Sponsored lecture II
13.55 - 14.10
Sponsored lecture III
13.25 - 14.10
Sponsored lunch session [parallel session]:
[session in Polish]
13.25 - 13.40
Sponsored lecture I
13.40 - 13.55
Sponsored lecture II
13.55 - 14.10
Sponsored lecture III
14.10 - 14.25
Coffee break
14.25 - 15.25
SESSION III – AML
[session in English]
14.25 - 14.40
Integrating novel therapies in front-line AML (from 3+7 to personalised therapy)
14.40 - 14.55
MRD in AML – prophylactic or pre-emptive approach?
14.55 - 15.10
Resistance to AZA/VEN – Houston, we have a problem
15.25 - 15.40
Coffee break
15.40 - 16.45
SESSION IV – SPONSORED LECTURES
[session in Polish]
16.10 - 16.25
Lecture III
16.45 - 17.00
Coffee break
17.00 - 18.15
SESSION V – ALL: "In uncharted waters"
[session in English]
17.00 - 17.25
Chemotherapy and allo-HCT for Ph (+) ALL – Has the ship sunk yet?
17.25 - 17.45
First-line treatment of patients with Ph (-) ALL – New coordinates
17.45 - 18.00
CAR-T in ALL – Destroyer or tugboat?
